IDDI @IDDI_Official

#IDDI hit the sand at the Axis Parc Beach Volley tournament! After intense rallies, strong teamwork, and a few “strategic” hydration breaks 🍻, we finished 17th out of 48 teams—just 9 points shy of the Top 16 😅 Big thanks to our players for the energy and great spirit on court!

#ProjectOptimus changed what "well-designed" means for early #oncology trials. We're resurfacing our 5-part podcast series with #IDDI's experts on dose-finding, PK/PD, #biostatistics and trial design. Check out the full series here: iddi.com/resources/#res… #ClinicalResearch

The right statistical strategy can make all the difference. In an NSCLC vaccine trial, a Bayesian adaptive approach identified responders, enriched the Phase 3 population & increased the probability of success—without adding patients. The full case study: iddi.com/resources/how-…

Some principles in clinical research are non-negotiable. Data over assumption. Evidence over expectation. Results over belief. #MarcBuyse sat down with @Clin_Trials for a five-part conversation on where the industry stands today. See the full interview: appliedclinicaltrialsonline.com/authors/marc-b…

Complex trial data. Tight timelines. Regulatory scrutiny. #IDDI supported a biotech developing a Geographic Atrophy treatment by leading the ISS/ISE strategy across multiple studies with different designs. The results: ✔FDA approval ✔EMA MAA accepted go.iddi.com/l/1100512/2026…

Congratulations to the #IDDI runners & walkers who participated and crossed the finish line of the @20kmbru last Sunday!! A great moment of team spirit, energy, and perseverance—values that also drive us every day in #clinicalresearch. Well done 🤩🎖️ #LifeAtIDDI #20kmDeBruxelles

Cancer prevention trials can take years to show results. How can sponsors make earlier development decisions with confidence? Marc Buyse explains how IDDI enabled earlier, data-driven decisions in a Lynch syndrome trial with interim analyses &endpoints tied to long-term outcomes.

What separates efficient #ophthalmology trials from delayed ones? It often comes down to the decisions made before the trial begins. Our latest guide outlines 5 data-driven steps to reduce risk, improve reliability, and keep ophthalmology studies on track: iddi.com/resources/5-da…

Clinical research is never the work of one person alone. In our final #ClinicalTrialsDay spotlight, Neil Baron reflects on the people behind every dataset, decision, and step forward in research. Today, we celebrate the people advancing research together! #CTD2026

Clinical trials are complex, but when the right people, processes, and data come together, meaningful progress happens. In our latest #CTD2026 spotlight, Tara Kervin shares how operational execution & data science working hand in hand can help research move faster for patients.

Not all contributions to patient care happen face-to-face with patients. In our latest #ClinicalTrialsDay spotlight, Françoise Dissassuca shares how clinical data management revealed a new way to make an impact through research. “Even behind the scenes, your work really matters.”

Variability, imaging inconsistency, and recruitment challenges can derail #ophthalmology trials. At #IDDI, we bring #biostatistics into study design early to reduce risk before it grows. Take a closer look: go.iddi.com/see-what-other… #SeeDataDifferently #ClinicalTrials

The wait is over! Tara Kervin presenting @10:50am "When the Truth Is in the Data: Independent Biometrics for Modern Clinical Trials”. If you're at #COGDMV, join this insightful session & visit us at booth #5 to connect, exchange ideas & discuss how #IDDI could support your study!

Behind every clinical trial is a team making research move forward every day. To celebrate #ClinicalTrialsDay, we’re launching a video series spotlighting the experts behind the scenes at #IDDI 🎥Joelle Perier shares why clean data is built from day one—not at the end of a study.

Most CRO selection decisions are made for convenience. But convenience doesn’t scale with complexity. That’s where risk creeps in. More and more teams are rethinking the generalist CRO model. Are you one of them? Book your strategy review today: go.iddi.com/l/1100512/2026…

Most biostatistics vendors will not challenge you—because they benefit from the status quo. Many teams are still running trials the same way. That’s where risk builds. Test it before it’s tested for you: go.iddi.com/l/1100512/2026… #ClinicalData

Is your #ophthalmology study built for success? Most ophthalmology trials fail at the recruitment stage – is that a design problem? See what others do not: go.iddi.com/see-what-other… #ClinicalTrials

600+ FDA submissions rejected due to study errors. Each one = delay, cost, and risk to patients. Most weren’t caused by “bad data”, they were caused by decisions made much earlier. Where is risk introduced in your trials? go.iddi.com/l/1100512/2026… #Regulatory #ClinicalData

Today’s clinical trials generate more data than ever. But more data = more complexity. That’s why biotech & pharma sponsors turn to specialist CROs like #IDDI. Hear from IDDI's COO on how to turn data complexity into a strategic advantage & how we can help go.iddi.com/l/1100512/2026…

Clinical trial data volume and complexity are rapidly increasing, but most vendor strategies have not changed to match. That mismatch is where timelines slip—and issues surface too late. Is your setup introducing risk? Find out: go.iddi.com/l/1100512/2026…